SUBOXONE

Phase 3

Indivior PLC (INDV.L)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Opioid Dependence

View Full Landscape

Drug Information

Target Indication

Opioid Dependence

Clinical Trial

NCT02357901

Last updated: 2/14/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA9/26/2006

Suboxone

Substitution treatment for opioid-drug dependence, within a framework of medical, social and psychological treatment. The intention of the naloxone component is to deter intravenous misuse. Treatment is intended for use in adults and adolescents over 15 years of age who have agreed to be treated for addiction.

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

INDV.L

Indivior PLC

Pharmaceutical Preparations•Europe•International

Related Pipeline

RBP-6000Phase 3

Opioid Use Disorder

Intranasal challenge drugPhase 3

Heroin Dependence